Regeneron Pharmaceuticals Says Linvoseltamab BLA For Treatment Of Relapsed/Refractory Multiple Myeloma Accepted For FDA Priority Review
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals announced that its Biologics License Application (BLA) for Linvoseltamab, aimed at treating relapsed/refractory multiple myeloma, has been accepted for FDA Priority Review. This expedited review process signifies the potential for Linvoseltamab to address an unmet medical need in the treatment of this cancer.
February 21, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals' BLA for Linvoseltamab in treating relapsed/refractory multiple myeloma has been accepted for FDA Priority Review, indicating a significant step forward in its development pipeline.
The acceptance of Regeneron's BLA for Linvoseltamab by the FDA for Priority Review is a positive development, indicating the treatment's potential to meet an unmet medical need. This news is likely to be viewed favorably by investors, as it not only highlights the company's innovative capabilities but also brings it a step closer to potentially adding a new product to its portfolio. The Priority Review status can expedite the review process, potentially leading to quicker market access and revenue generation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100